Form D · Pharmaceuticals
BioCritica, Inc.
Indianapolis, IN · CIK 0001521626
Offering snapshot reported May 26, 2011 · SEC filing
- Reported sold
- $25M Offering amount: $25M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 20, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 26, 2011 | Initial | $25,000,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-160380
Source: Form D, filed May 26, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Bologna | Director |
| David A. Broecker | Director, Executive |
| Darren Carroll | Director |
| Mike F. Johnson | Director |
| Argeris N. Karabelas | Director |
| Michael Pagnotta | Executive |
| Lorenzo Pellegrini | Director |
| Mark D. Williams | Executive |
| Ronald J. Wooten | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
8888 Keystone Crossing Suite 1300
Indianapolis, IN, 46240
Indianapolis, IN, 46240